期刊文献+

尿毒症出血性疾病的治疗 被引量:4

原文传递
导出
摘要 尿毒症出血性疾病是肾衰竭患者常见的并发症之一。早在100年前Reisman就曾描述过肾衰竭患者严重而广泛出血的临床表现。目前该病的病理生理机制尚未完全阐明,但一般认为由多种因素所致,其中血小板异常是引起尿毒症出血性疾病的主要因素。此外,贫血、药物及代谢产物在体内蓄积、血管功能异常及通透性增加、血液透析抗凝剂的使用等都可加重出血倾向。本文在回顾引起尿毒症患者出血可能的病理生理机制的基础上,重点对尿毒症出血性疾病的治疗作一综述。
作者 高翔 梅长林
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2007年第11期751-754,共4页 Chinese Journal of Nephrology
  • 相关文献

参考文献26

  • 1Fujimura Y, Matsumoto M, Yagi H, et al. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol, 2002, 75: 25-34.
  • 2Malyszko J, Malyszko JS, Mysliwiec M, et al. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis. Petit Dial Int, 2001, 21: 158-165.
  • 3Hedges SJ, Dehoney SB, Hooper JS, et al. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol, 2007, 3: 138-153.
  • 4Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood, 1999, 94: 2569- 2574.
  • 5Iseki K, Kinjo K, Kimura Y, et al. Evidence for high risk of cerebral hemorrhage in chronic hemodialysis patients. Kidney Int, 1993, 44: 1086-1090.
  • 6Sohal AS, Gangji AS, Crowther MA, et al. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res, 2006, 118: 417-422.
  • 7Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001, 345: 494-502.
  • 8Lai KN, Wang AY, Ho K, et al. Use of low-dose low molecular weight heparin in hemodialysis. Am J Kidney Dis, 1996, 28: 721-726.
  • 9Abramson S, Niles JL. Anticoagulation in continuous renal replacement therapy. Curr Opin Nephrol Hypertens, 1999, 8: 701-707.
  • 10Janssen MJ, van der Meulen J. The bleeding risk in chronic hemodialysis: preventive strategies in high-risk patients. Neth J Med, 1996, 48: 198-207.

同被引文献16

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部